|Bid||60.15 x 1000|
|Ask||60.16 x 1300|
|Day's Range||59.99 - 60.27|
|52 Week Range||46.10 - 62.69|
|Beta (5Y Monthly)||0.59|
|PE Ratio (TTM)||24.42|
|Forward Dividend & Yield||1.25 (2.05%)|
|Ex-Dividend Date||Mar 21, 2019|
|1y Target Est||N/A|
Today, Novo Nordisk launched the My$99Insulin Program, follow-on brands of insulins, and an Immediate Supply option, expanding its insulin affordability offering to help people with diabetes who need alternative solutions. These options, along with information on the existing patient assistance program, copay cards, and where to find $25/vial human insulin, are now available online at NovoCare.com or by calling 1.844.NOVO4ME (1.844.668.6463).
PHILADELPHIA, Nov. 19, 2019 /PRNewswire/ -- More than 100 health, faith, business and community leaders from across Philadelphia gathered today to learn about emerging research that identify general characteristics of neighborhoods that may make people more – or less – prone to developing type 2 diabetes, paving the way for more targeted interventions to prevent disease. As part of Cities Changing Diabetes, a global program sponsored by Novo Nordisk involving 25 cities around the world, these groups will be working together to develop new ways to try to change the trajectory of diabetes in Philadelphia.
MISSISSAUGA, ON , Sept. 10, 2019 /CNW/ - People living with diabetes are not the only ones impacted by the condition. Low blood sugar or "lows" as they are often referred to by people living with diabetes, are a well-known side-effect of diabetes treatment, especially when using insulin, and they can be very unpleasant and dangerous if not managed properly.
BOSTON, Aug. 14, 2019 /PRNewswire/ -- Wanted: high-potential life sciences and biotech start-up companies looking for an opportunity to be part of a vibrant innovation ecosystem where companies develop truly transformational science. Novo Nordisk, a global healthcare company committed to discovering, creating and co-creating innovation to solve healthcare challenges for people living with diabetes and other serious chronic diseases, issues an open call for promising start-up companies to submit non-confidential proposals for a Novo Nordisk-sponsored LabCentral "Golden Ticket." The winner will have the chance to receive access for one scientist and one bench at LabCentral's state-of-the-art shared lab space in Boston for research for one year.
PLAINSBORO, N.J., April 30, 2019 /PRNewswire/ -- Beginning in early 2020, Novo Nordisk's global production will be completely powered by renewable electricity, with a ten-year goal of achieving zero carbon emissions from operations and transportation. The announcement follows a $70 million investment in a 105-megawatt dc solar energy installation to be built in Pender County, North Carolina. When completed, ground-mounted solar arrays will harvest sunlight and provide renewable electricity to all existing Novo Nordisk US offices, laboratories and manufacturing facilities as well as to support the new manufacturing facility under construction in Clayton, N.C. Developed and constructed by Cypress Creek Renewables, the solar panel installation will be one of North Carolina's largest solar sites.
PLAINSBORO, N.J., March 1, 2019 /PRNewswire/ -- Novo Nordisk today announced that it recently submitted label updates to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for Fiasp® (insulin aspart injection) 100 u/mL, seeking approval for use as a new mealtime insulin for children and adolescents with type 1 diabetes. Fiasp® is currently approved to control high blood sugar in adults with diabetes. Managing diabetes around mealtimes can be hard1, with parents of young children with type 1 diabetes reporting that this was one of the most problematic areas2.
NEW YORK, Feb. 11, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.